The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Clinical Outcomes with Unselected Use of an Ultrathin-Strut Sirolimus-Eluting Stent: A Report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

DOI: 10.4244/EIJ-D-20-00429

1. Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden, Sweden
2. Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden
3. Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
4. Department of Cardiology, Västerås Hospital, Västerås, Sweden
5. Department of Clinical Science and Education, Karolinska Institutet, Unit of Cardiology, Södersjukhuset, Stockholm, Sweden
6. Örebro University, Faculty of Health, Department of Cardiology, Örebro, Sweden
7. Department of Cardiology, Danderyd University Hospital, Stockholm, Sweden
8. Coronary Artery Disease Area, Heart and Vascular Theme, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
Disclaimer:

As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention and external reviewers - has been published immediately upon acceptance as it was received in the last round of revision. The content of this article is the responsibility of the authors.

Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.

To read the full content of this article, please log in to download the PDF.

Aims: To assess the real-world clinical performance of a sirolimus-eluting ultrathin-strut drug-eluting stent (DES) [Orsiro, Biotronik AG] in a large nationwide cohort of patients undergoing percutaneous coronary intervention (PCI).

Methods and results: From the Swedish Coronary Angiography and Angioplasty Registry, the 2-year outcomes of 4,561 patients implanted with Orsiro (Orsiro group) and 69,570 receiving other newer generation DES (n-DES group) were analyzed. The rate of definite stent thrombosis was low in both groups (0.67% and 0.83% for Orsiro and n-DES, respectively; adjusted hazard ratio [HR] 0.90, 95% confidence interval [CI] 0.55-1.46, p-value 0.66). Restenosis was also infrequent (1.5% versus 2.0% with Orsiro and n-DES, adjusted HR 0.81, 95% CI 0.63-1.03, p-value=0.09). The risk of target lesion revascularization by PCI was lower in the Orsiro group (1.6% versus 2.3%, adjusted HR 0.75, 95% CI 0.60-0.94, p-value=0.013). All-cause mortality and myocardial infarction did not show a statistically significant difference between the two groups (mortality of 7.5% in both groups, adjusted HR 0.99, 95% CI 0.72-1.35, p-value=0.94; 6.0% versus 5.2% for myocardial infarction, adjusted HR 1.19, 95% CI 1.00-1.43, p-value=0.06).

Conclusions: In a nationwide scenario, the use of a sirolimus-eluting ultrathin-strut DES portended favorable clinical outcomes.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Predictors and outcomes of neoatherosclerosis in patients with in-stent restenosis